Trump administration advances plan for peptide drugs favored by RFK Jr.

AI justification

Policy weakens regulatory oversight and risks patient harm, outweighing potential medical benefits. | While the plan may improve access to medical innovations (SDG 3, 9), the lack of regulatory oversight and potential for harm to patients (UDHR Article 25) outweighs these benefits. The influence of non-scientific actors further erodes trust in public health institutions, creating long-term ethical risks.